The Study To Test The Effect of Standardization Of Fluid Intake In Female Patients With Overactive Bladder

GlaxoSmithKline (GSK)

Status and phase

Completed

Phase 1

Conditions

Overactive Bladder

Treatments

Drug: DETROL LA (drug)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00553657

BKB105190

Details and patient eligibility

About

The purpose of this study is to determine if standardizing fluid intake in a clinic setting will reduce variability of individual voiding parameters and potentially serve as a way to limit patient exposure in the initial assessment of efficacy of compounds being developed for Overactive Bladder.

Enrollment

55 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Eligible participants will be females who are 18 years of age or older, with Overactive Bladder as evidenced by daily episodes of urgency without incontinence, which may be associated with frequency or nocturia but without bladder pain. At screening, eligible patients must report frequency, defined as at least 8 micturitions per 24 hour period.
Eligible patients must have signed the informed consent and must meet all inclusion and exclusion criteria as determined during the screening visit.

Exclusion criteria

Any abnormality identified on the screening examination or any other medical condition or circumstance making the patient unsuitable for participation in the study based on the Investigator's and Medical Monitor's assessment
Any contraindication to Detrol LA or other anti-muscarinic medications
Inability to consume 10 cc/kg of fluid within 30 minutes
Regular alcohol consumption averaging ³7 drinks/week for women (1 drink = 100mL of wine or 285mL of beer or 30mL of hard liquor)
Positive urine drug or alcohol at screening at screening
Average blood pressure measurements systolic ≥140 or diastolic ≥90 at screening at screening
QTcB value ≥ 450 msec at screening
Poorly-controlled diabetes mellitus or hypertension, as evidenced by a change in medication within the 2 months prior to initiation of the study
History of urinary retention or gastric retention
Known history of narrow-angle glaucoma
History of QT prolongation
Known reduction in hepatic or renal function
Concomitant Use of loop diuretics (eg. Furosemide)
Concomitant use of a medication that is a potent inhibitor of CYP3A4
Class IA or Class III antiarrhythmic medications
Patient is unable and/or unwilling to adhere to Lifestyle Guidelines
For women of child bearing potential, a positive serum β-hCG at screening or pre-dose, or an unwillingness to agree to adequate contraception from the time of screening until the completion of the study:
Positive for hepatitis C antibody, hepatitis B surface antigen or HIV at screening.
Presence of urinary tract infection within 4 weeks of screening.
Post-void residual of >150 mL (bladder ultrasound).